Strides Pharma Science Ltd (STAR) is currently trading at 1,057.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Strides Pharma Science Limited is a global pharmaceutical company manufacturing and exporting branded and generic finished dosage forms, including tablets, capsules, softgels, parenterals, semisolids, nasal sprays, patches and films. Its businesses span the US, Ex-US markets and tactical access operations, supported by global regulatory, manufacturing and commercial infrastructure. Strides Pharma Science Limited delivered Q2FY27 revenue of ₹14,297 million, up 17.1% year over year, while EBITDA crossed ₹2,500 million for the first time. Growth was led by Ex-US markets, which expanded 31% and surpassed US quarterly revenue for the first time, demonstrating that geographic diversification is becoming a meaningful growth engine. The company’s US growth remains positive but more measured, with H1FY27 revenue up 7% as drug-shortage opportunities normalized, controlled-substance quotas constrained expansion and operating costs increased. Management has therefore shifted emphasis toward differentiated products such as nasal sprays, patches, films and controlled substances while preserving profitability thresholds. Strides Pharma Science Limited faces a meaningful working-capital challenge: net debt increased ₹2,114 million during H1FY27 to ₹16,479 million, while the cash-to-cash cycle lengthened to 137 days. Management expects leverage to stabilize by year-end, but inventory, receivables and higher finance costs remain important variables for cash generation. The company’s US platform includes 154 approved products, 75 commercialized products and 38 products holding market-leading positions, contributing approximately 70% of US revenue. Its controlled-substance portfolio currently contributes about 6% of US revenue, with a larger pipeline and substantial stated addressable market offering potential upside if quota availability improves.

Over the past 52 weeks, Strides Pharma Science Ltd has traded between a low of ₹769.60 and a high of ₹1,260.10. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Strides Pharma Science Ltd has a market capitalization of approximately 10,115.03. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Strides Pharma Science Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.88 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 10,115.03 Cr, Strides Pharma Science Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Strides Pharma Science Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Strides Pharma Science Ltd is 15.88. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Strides Pharma Science reported consolidated Q2 FY27 revenue of ₹1,429.7 crore, rounded to ₹1,430 crore.

Strides Pharma reported consolidated revenue of ₹1,265.40 crore (₹12,654 million) in Q1 FY27, up 13% year-on-year.

Revenue from operations rose 13.0% year-on-year to ₹12,654.07 million in Q1 FY27.

Strides Pharma Science reported consolidated reported PAT of ₹165.49 crore in Q1 FY27, a 56.7% increase year-on-year.